Garmisch

Garmisch Therapeutics is a pre-clinical stage biotechnology company dedicated to discovering and developing transformative therapies for neurodegenerative disorders, with a primary focus on Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Founded by Dr. Aaron Gitler, a leading Stanford University researcher, the company leverages deep genetic insights into RNA-binding proteins and protein aggregation to identify novel therapeutic targets. Garmisch is particularly focused on modulating genetic modifiers of TAR DNA-binding protein 43 (TDP-43) toxicity, a central pathological feature of several neurodegenerative conditions. Backed by ARCH Venture Partners, the company utilizes advanced screening platforms to develop disease-modifying small molecules and genetic medicines. Its approach aims to address the underlying biological drivers of protein misfolding and neurodegeneration to provide hope for patients with high unmet medical needs.